Real-World data suggests asciminib may help some leukemia patients
NCT ID NCT07644351
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study reviewed medical records of 37 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who took asciminib because other treatments stopped working or caused side effects. Researchers wanted to see how many patients achieved complete remission within three months. The study is completed and provides real-world insight, but it was small and not a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib
What this could lead to
If results are positive, asciminib could offer a new treatment option for adults with Ph+ ALL who have run out of other choices.
What could go wrong
This is a small, retrospective chart review (37 patients), not a controlled trial. Results may not apply to all patients, and safety data is limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Boston, Massachusetts, 02115, United States
-
Novartis Investigative Site
Sydney, New South Wales, 2145, Australia
-
Novartis Investigative Site
Montreal, H1T 2M4, Canada
-
Novartis Investigative Site
Hong Kong, China
-
Novartis Investigative Site
Le Chesnay, 78150, France
-
Novartis Investigative Site
Ramat Gan, 52621, Israel
-
Novartis Investigative Site
Ascoli Piceno, 63100, Italy
-
Novartis Investigative Site
Bari, 70124, Italy
-
Novartis Investigative Site
Catania, 95123, Italy
-
Novartis Investigative Site
Cuneo, 12100, Italy
-
Novartis Investigative Site
Pescara, 65124, Italy
-
Novartis Investigative Site
Torino, 10126, Italy
-
Novartis Investigative Site
Rotterdam, 3015, Netherlands
-
Novartis Investigative Site
Islamabad, 44000, Pakistan
-
Novartis Investigative Site
Rawalpindi, 46000, Pakistan
-
Novartis Investigative Site
Bialystok, 15-276, Poland
-
Novartis Investigative Site
Madrid, 28006, Spain
-
Novartis Investigative Site
London, SE5 9RS, United Kingdom